Standards of Care & Cardiovascular Goals in Diabetes

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/51

flashcard set

Earn XP

Description and Tags

Vocabulary practice flashcards covering clinical definitions, diagnostic thresholds, landmark trials, screening criteria, and therapeutic targets from the ADA Standards of Care and Cardiovascular Goals lecture.

52 Terms

1
New cards

Population Health

The health outcomes of a group of individuals, including the distribution of outcomes within the group, measured via mortality, morbidity, health status, functional status, disease burden (incidence and prevalence), and behavioral or metabolic factors.

2
New cards

General Population Diabetes Screening Guideline

Universal screening for prediabetes and type 2 diabetes recommended for all asymptomatic individuals starting at age 3535, repeated at a minimum of 3-year3\text{-year} intervals if results are normal.

3
New cards

Risk-Based Screening for Type 2 Diabetes

Screening performed at any age in asymptomatic adults with a BMI⋈≥25 kg/m2\text{BMI} \bowtie \ge 25\,\text{kg/m}^2 (≥23 kg/m2\ge 23\,\text{kg/m}^2 in Asian Americans) who have one or more additional risk factors, such as a first-degree relative with diabetes, high-risk ethnicity, physical inactivity, or history of cardiovascular disease.

4
New cards

Cystic Fibrosis-Related Diabetes (CFRD) Screening

Annual screening beginning at age 1010 using an Oral Glucose Tolerance Test (OGTT). A1C is not recommended as a screening tool for CFRD. (Beginning 5 years after the diagnosis of

CFRD, annual monitoring for complications

of diabetes is recommended.)

5
New cards

Post-Transplantation Diabetes Mellitus (PTDM)

Hyperglycemia detected after organ transplantation screened via OGTT once the recipient is stable on an immunosuppressive regimen and free of acute infection.

6
New cards

Prediabetes Diagnostic Criteria

A biochemical classification defined by an A1C of 5.7–6.4%5.7\text{--}6.4\% or a fasting plasma blood glucose of 100–125 mg/dL100\text{--}125\,\text{mg/dL}.

7
New cards

Diabetes Prevention Program (DPP)

A landmark clinical trial showing that an intensive lifestyle intervention achieving 5–7%5\text{--}7\% weight loss and 150 minutes150\,\text{minutes} of weekly physical activity reduced the risk of developing type 2 diabetes by 58%58\% in individuals with prediabetes.

8
New cards

Sleep Quality (in Diabetes Risk)

An individual's self-satisfaction with all aspects of the sleep experience; poor sleep quality is associated with a 40%40\% increased risk of developing type 2 diabetes.

9
New cards

Evening Chronotype (Night Owls)

A circadian rhythm preference associated with 2.5 times2.5\text{ times} higher odds of developing type 2 diabetes compared to morning chronotypes (early birds).

10
New cards

Metformin for Prediabetes Prevention

Preventive pharmacotherapy considered for high-risk individuals aged 25–59 years25\text{--}59\,\text{years} with BMI≥35 kg/m2\text{BMI} \ge 35\,\text{kg/m}^2, A1C≥6.0%\text{A1C} \ge 6.0\%, or a history of gestational diabetes mellitus (GDM).

11
New cards

GLP-1 Therapy in Prediabetes

Glucagon-like peptide 1-based therapy used for weight management in individuals with BMI≥25 kg/m2\text{BMI} \ge 25\,\text{kg/m}^2, where each kilogram of weight loss produces a 16%16\% risk reduction of progression to diabetes over 3.2 years3.2\,\text{years}.

12
New cards

Estimated Average Glucose (eAG)

A calculated average blood glucose derived from the A1C level using the formula eAG=28.7×A1C−46.7\text{eAG} = 28.7 \times \text{A1C} - 46.7, corresponding to roughly 29 mg/dL29\,\text{mg/dL} for each 1%1\% increment in A1C.

13
New cards

Fructosamine Test

A lab test measuring glucose bound to albumin reflecting glycemic control over the preceding 2–4 weeks2\text{--}4\,\text{weeks}, useful during pregnancy, rapid treatment alterations, or conditions with altered red blood cell turnover where A1C is unreliable.

14
New cards

Time in Range (TIR)

The percentage of time an individual's glucose levels remain within the target window of 70–180 mg/dL70\text{--}180\,\text{mg/dL}, with a standard clinical goal of >70%> 70\% of readings for most non-pregnant adults.

15
New cards

Time Below Range (TBR)

Continuous glucose monitoring metric tracking hypoglycemia; clinical targets for non-frail adults are <4%< 4\% of time below 70 mg/dL70\,\text{mg/dL} and <1%< 1\% of time below 54 mg/dL54\,\text{mg/dL}.

16
New cards

Time Above Range (TAR)

Continuous glucose monitoring metric tracking hyperglycemia; standard targets are <25%< 25\% of time above 180 mg/dL180\,\text{mg/dL} and <5%< 5\% of time above 250 mg/dL250\,\text{mg/dL}.

17
New cards

Ambulatory Glucose Profile (AGP)

A standardized, single-page visual report that presents continuous glucose monitoring metrics including Time in Range, Glucose Management Indicator (GMI), average glucose, and glucose variability.

18
New cards

Glucose Variability Target (%CV)

A continuous glucose monitoring stability metric calculated as the percent coefficient of variation, with a standard target of ≤36%\le 36\%.

19
New cards

Diabetes Control and Complications Trial (DCCT)

A landmark 10-year study of over 1,4001,400 participants with type 1 diabetes showing that intensive glycemic control (\text{A1C} < 7\%$) reduced eye disease by 76\%,kidneydiseaseby, kidney disease by50\%,andnervediseaseby, and nerve disease by60\%$$.

20
New cards

United Kingdom Prospective Diabetes Study (UKPDS)

A landmark 20-year study of over 5,1005,100 patients with type 2 diabetes establishing that each 1%1\% decrease in A1C reduced microvascular complications by 35%35\% and diabetes-related deaths by 25%25\%.

21
New cards

Legacy Effect

The enduring long-term reduction in microvascular and macrovascular complications over 20 to 30 years resulting from early, intensive blood glucose control, even if A1C levels subsequently increase.

22
New cards

Cardiometabolic Risk: The 5 Hypers

Five clinical manifestations associated with insulin resistance syndrome: hyperinsulinemia, hyperglycemia, hyperlipidemia, hypertension, and hyper'waistline'emia (≥35 inches\ge 35\,\text{inches} in women, ≥40 inches\ge 40\,\text{inches} in men).

23
New cards

Cardiorenal Metabolic Disease

The interconnected clinical triad of atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), and chronic kidney disease (CKD) driven by shared metabolic risk factors in diabetes.

24
New cards

Albuminuria Diagnostic Threshold

A persistent urinary albumin-to-creatinine ratio (UACR) of ≥30 mg/g\ge 30\,\text{mg/g}, which dictates the selection of an ACE inhibitor or ARB as first-line blood pressure therapy in diabetes.

25
New cards

Dual Antihypertensive Initiation Threshold

A confirmed blood pressure reading of ≥150/90 mmHg\ge 150/90\,\text{mmHg}, requiring the immediate simultaneous initiation of two antihypertensive agents from complementary drug classes.

26
New cards

High-Intensity Statin Therapy

Statin therapy designed to lower LDL cholesterol by ≥50%\ge 50\%, consisting of atorvastatin 40–80 mg40\text{--}80\,\text{mg} daily or rosuvastatin 20–40 mg20\text{--}40\,\text{mg} daily.

27
New cards

Moderate-Intensity Statin Therapy

Statin therapy that lowers LDL cholesterol by 30–49%30\text{--}49\%, including atorvastatin 10–20 mg10\text{--}20\,\text{mg}, rosuvastatin 5–10 mg5\text{--}10\,\text{mg}, simvastatin 20–40 mg20\text{--}40\,\text{mg}, or pravastatin 40–80 mg40\text{--}80\,\text{mg}.

28
New cards

LDL Target: Secondary ASCVD Prevention

A target reduction in LDL cholesterol of ≥50%\ge 50\% from baseline to achieve an absolute goal of <55 mg/dL< 55\,\text{mg/dL} (<1.4 mmol/L< 1.4\,\text{mmol/L}) in individuals with diabetes and established ASCVD.

29
New cards

LDL Target: Primary Prevention with Risk Factors

A recommended LDL cholesterol reduction of ≥50%\ge 50\% from baseline to achieve a goal of <70 mg/dL< 70\,\text{mg/dL} (<1.8 mmol/L< 1.8\,\text{mmol/L}) for individuals aged 40–75 years40\text{--}75\,\text{years} with diabetes and at least one cardiovascular risk factor.

30
New cards

Secondary Prevention Antiplatelet Strategy

The use of aspirin (75–162 mg/day75\text{--}162\,\text{mg/day}) or clopidogrel (75 mg/day75\,\text{mg/day} if aspirin-allergic) in individuals with diabetes and established ASCVD.

31
New cards

Dual Pathway Antithrombotic Therapy

Combination therapy with aspirin 81 mg81\,\text{mg} once daily plus rivaroxaban 2.5 mg2.5\,\text{mg} twice daily to prevent major adverse limb and cardiovascular events in patients with stable CAD/PAD and low bleeding risk.

32
New cards

Finerenone

A nonsteroidal mineralocorticoid receptor antagonist (MRA) indicated for patients with type 2 diabetes and chronic kidney disease to reduce the risk of hospitalization for heart failure.

33
New cards

4Ms Framework

An age-friendly health systems framework that focuses geriatric care on four core elements: What Matters Most, Medications, Mentation, and Mobility.

34
New cards

Glycemic Goal De-Intensification

Relaxing glycemic targets to an A1C<8.0%\text{A1C} < 8.0\%, TIR≥50%\text{TIR} \ge 50\%, and TBR≤1%\text{TBR} \le 1\% for older adults with complex health, intermediate life expectancy, high treatment burden, or severe hypoglycemia risk.

35
New cards

Hyperglycemic Ketosis-Cannabis Hyperemesis Syndrome

A distinct presentation in adolescents with type 1 diabetes and ketosis characterized by normal or near-normal acid-base balance (pH≥7.4\text{pH} \ge 7.4 and bicarbonate >15 mmol/L> 15\,\text{mmol/L}) driven by recreational cannabis use.

36
New cards

Pneumococcal Conjugate Vaccine (PCV) Schedule

Immunization for adults aged 19–64 years19\text{--}64\,\text{years} with diabetes using either a single dose of PCV20 or PCV15 followed by PPSV23 at least 1 year1\,\text{year} later.

37
New cards

Zoster Vaccine (Shingrix)

A 2-dose recombinant shingles vaccine recommended for all adults with diabetes aged ≥50 years\ge 50\,\text{years}.

38
New cards

Hepatitis B Vaccination Schedule

A 2-to-3 dose vaccination series recommended for all unvaccinated adults with diabetes aged ≤60 years\le 60\,\text{years}.

39
New cards

RSV Vaccine

A single-dose respiratory syncytial virus vaccine recommended for adults with diabetes aged ≥60 years\ge 60\,\text{years}.

40
New cards

What is the preferred approach when providing diabetes education to

a child with type one diabetes on an insulin pump?

a. Individualize goals based on assessment

b. Encourage parents to collaborate to meet national standards

c. Highlight risk of complications when goals aren’t achieved

d. Gently remind them that insulin therapy improves outcomes.

Individualize goals based on assessment

41
New cards

According to ADA 2026 Standards, who should be screened for

prediabetes/ diabetes?

a. JR, has family history of diabetes, BMI 22, age 32

b. MS, age 37

c. LK, smokes, has HTN age 33

d. RA, Hispanic, low HDL, avg wt

b. MS, age 37

42
New cards

According to the Diabetes Prevention Program (DPP), losing 5-7 % of body

weight and accumulating 150 minutes activity a week can:

a. Help prevent type 1 diabetes

b. Lower risk of getting prediabetes

c. Decrease risk of getting diabetes

d. Prevent type 2 diabetes

Prevent type 2 diabetes

43
New cards

JL is 59 years old with type 1 diabetes. JL tells you they got their Herpes Zoster and pneumococcal vaccine. What other vaccines

are recommended for JL?

1. Influenza vaccine and Hepatitis B

2.Pneumonia and Human Papilloma Virus (HPV)

3. TDAP and Pneumonia

4.COVID and Human Papilloma Virus (HPV)

1. Influenza vaccine and Hepatitis B

44
New cards

LS is currently unemployed and without health insurance. LS takes Metformin 500mg BID and tells you they can’t afford strips to check their blood

glucose daily. What is the best response?

a. Inform provider that LS is non-adherent due to financial issues

b. Encourage LS to borrow strips from friends or trusted relatives

c. Set up a fund for uninsured for this purpose

d. Check LS’s blood glucose levels at each office visit

d. Check LS’s blood glucose levels at each office visit

45
New cards

JL is 78 and drinks a “few cocktails” every night. Lives with partner and takes

basal insulin at night and bolus insulin as needed. Checks BG a

few times a week. Most recent A1C was 5.5%. What is a safe

Time in Range Target (TIR) for JL? A. TIR of 80%, below

range less than 10% B. TIR 50%, below

range less than 1% C. Ask JL to determine their TIR target

D. Keep coefficient of variation less than 36%.

TIR 50%, below range less than 1%

46
New cards

According to the American Association of Clinical Endo (AACE), what is the

A1C goal?a. Less than 6.5 for all people with diabetes

b. Pre meal blood glucose less than 110

c. A1C less than 7%

d. A1C less than 6.5 for healthy individuals

d. A1C less than 6.5 for healthy individuals

47
New cards

Which study demonstrated that keeping A1C less than 7% reduces

complications for Type 1?

a. Diabetes Prevention Trial

b. Diabetes Control and Complications Trial

c. United Kingdom Prospective Diabetes Study

d. YOUTH Trial

b.Diabetes Control and Complications Trial

48
New cards

Which of the following BEST describes insulin resistance?

a. Lack of sufficient insulin receptors on fat and muscle cells.

b. Excess visceral adipose tissue.

c. A physiological condition where insulin becomes less effective at lowering blood glucose levels.

d. Upregulation of GLUT-4 transporters on cell surface

c. A physiological condition where insulin becomes less effective at lowering blood glucose levels.

49
New cards

WS has a history of a stroke, diabetes for 12 years and smokes

a pack a day. Which of the following actions would most

reduce risk of a future CV event?

a. Lose 5-7% of body weight

b. Stop smoking

c. Start aspirin therapy

d. Initiate a Mediterranean Diet

b. Stop smoking

50
New cards

78 year old, A1C 7.3, LDL 86, B/P 102/54 GFR 58, UACR

36mg/g. C/o of dizziness. Hx of stroke. Based on ADA guidelines, what

meds missing?Current Meds: Insulin – 16 units glargine at HS

Losartan 25 mg

Metoprolol 50mg

Glipizide 20mg in am

a. Metformin and ARB

b. Vitamin D and SGLT2

c. Bolus insulin and ACE

d. Statin and Aspirin

d. Statin and Aspirin (Secondary Cardiovascular Prevention: This patient has diabetes and a history of stroke, which classifies them as having established atherosclerotic cardiovascular disease (ASCVD). For these individuals, the American Diabetes Association (ADA) Standards of Care strongly recommend secondary prevention therapies. [1]

  • Missing Statin: A high-intensity statin is indicated for secondary prevention in patients with established ASCVD to mitigate further cardiovascular and cerebrovascular events, regardless of the baseline LDL level. This patient has an LDL of 86 mg/dL and is not currently on a lipid-lowering medication. [1]

  • Missing Aspirin: Antiplatelet therapy with low-dose aspirin is indicated as a secondary prevention strategy for patients with a documented history of ASCVD to reduce the risk of recurrent stroke or myocardial infarction)


51
New cards

Based on this case study,which first concern are you

going to address?

a. Monitoring salt intake.

b. Weight loss counseling.

c. Keeping conversation person centered.

d. Blood pressure monitoring.

d. Blood pressure monitoring.

52
New cards

RT, is a healthy 74-year-old who is on metformin 1000mg BID. He has had diabetes for 11 years. His latest A1C was 7.3% What is

best response? A. Good job, let’s get the A1C less than 7% B. Have you been snacking more than

usual? C. What do you think about your A1C level? D. Let’s add on another medication to get your A1C to target.

C. What do you think about your A1C level? (Patient-Centered Communication: Leading with an open-ended question is a core clinical technique used to assess the patient's own understanding, perception, and attitude toward their health data before jumping into adjustments or assumptions.

  • Individualized Glycemic Targets: According to the American Diabetes Association (ADA) guidelines for older adults, glycemic targets should be individualized based on overall health status. For a healthy 74-year-old with few co-morbidities, a reasonable and safe A1C target is usually < 7.5% (or < 7.0% if there is an exceptionally long life expectancy and low risk of hypoglycemia). Because RT's A1C is 7.3%, he is actually within a very acceptable clinical range for his age group)